S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Price, News & Analysis

$4.41
-0.05 (-1.12%)
(As of 03/1/2024 ET)
Today's Range
$4.40
$4.58
50-Day Range
$0.65
$6.22
52-Week Range
$3.66
$14.50
Volume
20,009 shs
Average Volume
16,796 shs
Market Capitalization
$23.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

SAB Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
126.8% Upside
$10.00 Price Target
Short Interest
Healthy
0.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of SAB Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1,531 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.64) to ($2.96) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

429th out of 951 stocks

Biological Products, Except Diagnostic Industry

68th out of 158 stocks


SABS stock logo

About SAB Biotherapeutics Stock (NASDAQ:SABS)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SABS Stock Price History

SABS Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
SAB Biotherapeutics Names Samuel Reich Chief Executive
SAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEO
SAB Biotherapeutics Announces Executive Leadership Change
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
SAB Biotherapeutics GAAP EPS of -$0.10
See More Headlines
Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/21/2023
Today
3/01/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SABS
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+126.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-18,740,000.00
Net Margins
-664.68%
Pretax Margin
-664.04%

Debt

Sales & Book Value

Annual Sales
$23.90 million
Book Value
$7.22 per share

Miscellaneous

Free Float
3,874,000
Market Cap
$23.06 million
Optionable
Not Optionable
Beta
0.90
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Samuel J. Reich (Age 49)
    CEO & Executive Chairman
    Comp: $376.2k
  • Dr. Eddie Joe Sullivan Ph.D. (Age 57)
    Co-Founder, President & Director
    Comp: $430.62k
  • Ms. Christine E. Hamilton M.B.A. (Age 68)
    Co-Founder & Independent Director
    Comp: $25k
  • Dr. Alexandra Kropotova M.B.A. (Age 51)
    M.D., Executive VP & Chief Medical Officer
    Comp: $486.96k
  • Dr. Edward D. Hamilton D.V.M.
    Co-Founder & Board Observer
  • Mr. Michael George King Jr. (Age 63)
    EVP & CFO
  • Dr. Christoph Bausch M.B.A. (Age 53)
    Ph.D., Executive VP & COO
  • Dr. Carlos N. Carillo Ph.D.
    Senior Vice President of Regulatory Affairs














SABS Stock Analysis - Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SABS shares.
View SABS analyst ratings
or view top-rated stocks.

What is SAB Biotherapeutics' stock price target for 2024?

2 equities research analysts have issued 1-year price targets for SAB Biotherapeutics' shares. Their SABS share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 126.8% from the stock's current price.
View analysts price targets for SABS
or view top-rated stocks among Wall Street analysts.

How have SABS shares performed in 2024?

SAB Biotherapeutics' stock was trading at $0.6875 at the beginning of 2024. Since then, SABS stock has increased by 541.5% and is now trading at $4.41.
View the best growth stocks for 2024 here
.

When is SAB Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our SABS earnings forecast
.

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) released its earnings results on Monday, August, 21st. The company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14). The company had revenue of $0.09 million for the quarter. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 120.36% and a negative net margin of 664.68%.

Who are SAB Biotherapeutics' major shareholders?

SAB Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (175.49%), BVF Inc. IL (175.43%), Commodore Capital LP (35.02%), Vanguard Group Inc. (19.04%), Pathstone Holdings LLC (9.68%) and Kestra Advisory Services LLC (1.68%). Insiders that own company stock include Christine E Hamilton, Eddie Joe Sullivan, Michael King and Samuel J Reich.
View institutional ownership trends
.

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SABS) was last updated on 3/2/2024 by MarketBeat.com Staff